Evaluation of a Pragmatic NT-ProBNP-based Heart Failure Screening Strategy Among Patients With Type 2 Diabetes: STRONG-DM Study (Screening and Treatment Using Risk-based apprOach With NT-ProBNP Guidance in Diabetes Mellitus
The STRONG-DM study, sponsored by the University of Texas Southwestern Medical Center, aims to evaluate a pragmatic heart failure screening strategy utilizing NT-proBNP and clinical risk scores among patients with Type 2 Diabetes. This study is particularly relevant given the increasing prevalence of diabetes and associated cardiovascular complications, representing a significant market opportunity for preventive therapies such as SGLT2 inhibitors and GLP-1 agonists. The collaboration with Roche Diagnostics indicates potential for leveraging diagnostic capabilities, which could enhance the commercial viability of the intervention. The outcomes may influence clinical guidelines and reimbursement strategies, impacting market dynamics for heart failure management in diabetic patients.
Indication: Type 2 Diabetes
Modality: behavioral intervention
Target: NT-proBNP (N-terminal pro b-type Natriuretic Peptide) as a biomarker for heart failure risk assessment in patients with Type 2 Diabetes.
Sponsor: University of Texas Southwestern Medical Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 03, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: NT-proBNP (N-terminal pro b-type Natriuretic Peptide) as a biomarker for heart failure risk assessment in patients with Type 2 Diabetes.
View original source fields
Condition raw: Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
Condition normalized: Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
Modality raw: behavioral intervention
Modality normalized: behavioral intervention
Target raw: NT-proBNP (N-terminal pro b-type Natriuretic Peptide) as a biomarker for heart failure risk assessment in patients with Type 2 Diabetes.
Target normalized: NT-proBNP (N-terminal pro b-type Natriuretic Peptide) as a biomarker for heart failure risk assessment in patients with Type 2 Diabetes.